MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
DMAC DiaMedica Therapeutics
- 6.410
- +1.540+31.62%
Close Dec 20 16:00 ET
- 5.650
- -0.760-11.86%
Post 19:58 ET
274.10MMarket Cap-11.45P/E (TTM)
6.410High4.750Low265.81KVolume4.760Open4.870Pre Close1.59MTurnover1.10%Turnover RatioLossP/E (Static)42.76MShares6.41052wk High5.71P/B154.51MFloat Cap2.14052wk Low--Dividend TTM24.10MShs Float10.880Historical High--Div YieldTTM34.09%Amplitude1.120Historical Low5.993Avg Price1Lot Size
About DiaMedica Therapeutics Company
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
Company Profile
SymbolDMAC
Company NameDiaMedica Therapeutics
Listing DateDec 7, 2018
Issue Price4.00
Founded2000
CEOMr. Rick Pauls
MarketNASDAQ
Employees19
Fiscal Year Ends12-31
Address301 Carlson Parkway,Suite 210
CityMinneapolis
ProvinceMinnesota
CountryUnited States of America
Zip Code55305
Phone1-763-496-5454
Websitehttp://www.diamedica.com
Company Executives
- Name
- Position
- Salary
- Rick Pauls
- Director, President and Chief Executive Officer
- 1.22M
- Scott Kellen
- Chief Financial Officer, Principal Accounting Officer and Secretary
- 632.22K
- Lorianne Masuoka
- Chief Medical Officer
- --
- Lorianne Musuoka
- Chief Medical Officer
- --
- David J. Wambeke
- Chief Business Officer
- --
- Dominic R. Cundari
- Chief Commercial Officer
- --
- Rebekah de Vitry Fries
- Vice President of Clinical Operations
- --
- Julie VanOrsdel Daves
- Senior Vice President, Clinical Development Operations
- 533.37K
- Richard D. Pilnik
- Chairman of the Board
- 133.98K
- Charles Semba, M.D.
- Independent Director
- 89.68K
- Dr. Michael Giuffre, M.D.
- Independent Director
- 90.93K
- Tanya Lewis, M.S.
- Independent Director
- 91.85K
- James T. Parsons
- Independent Director
- 97.18K
- Dr. Richard E. Kuntz, M.D.,M.Sc.
- Independent Director
- 96.02K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
